Healthcare

The sharp rally comes despite CSL reporting aUS$2.6 billion statutory net lossfor FY26, with the market instead focusing on the company’s underlying earnings, strong cash generation, cost-cutting progress, resilient plasmaBusinessand a freshA$1.1 billion share buy-back.

Pro Medicus Ltd (ASX:PME) has reported its FY26 full-year results, highlighting continued growth across its healthcare imaging software platform, increased profitability, new customer agreements and further development of artificial intelligence-enabled products.

Cogstate (ASX:CGS) delivered record financial and commercial results for FY26, supported by higherDemandfor its clinical trial endpoint services across central nervous system disorders. Revenue from operations increased 15% to US$60.9 million from US$53.1 million in FY25, while record netClinical Trialssales contracts rose 116% to …

CSL Limited (ASX:CSL) described FY26 as a reset year as the healthcare company reported lower underlying earnings, broadly flat revenue and a significant statutory loss following largeImpairmentand restructuring charges. Total revenue was US$15.8 billion, down 1% at constant currency, while underlying NPATA attributable to …

Cochlear (ASX:COH) delivered sales revenue of $2.343 billion for FY26, representing a 2% increase in constant-currency terms. Growth accelerated in the second half, with constant-currency revenue up 6%, placing the company at the upper end of the revised guidance issued in April.

Epiminder's most recent disclosures were its Q4 FY26 quarterly activities report and Appendix 4C plus an FY26 investor presentation, both released on 30 July 2026, and a 16 July 2026 update confirming the 50th enrolment in its US DETECT reimbursement study.

Regal Partners Funds Management lifted its stake to 10,296,225 shares, or 9.14% of the register, from 7.91% disclosed in April, with the change dated 13 August. An activeFund Manageradding in the week before a results release is the kind of signal small-cap investors notice, …